ATXN2 and frontotemporal dementia: Another group also identified that ASOs targeting ataxin 2 could suppress neurodegeneration in ALS and frontotemporal dementia (FTD) mediated by a GGGGCC hexanucleotide repeat expansion in patient-derived neurons (Zhang et al., 2018).